Harrow (HROW) Asset Writedowns and Impairment (2016 - 2026)
Harrow's (HROW) quarterly Asset Writedowns and Impairment came in at -$195000.0 in Q1 2026, down 271.05% year-on-year from $114000.0 in Q1 2025, and down 143.75% quarter-over-quarter from -$80000.0 in Q4 2025.
Harrow (HROW) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Harrow's Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at -$195000.0 for Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 271.05% year-over-year to -$195000.0 in Q1 2026; TTM through Mar 2026 was $159000.0, a 50.16% decrease from a year earlier, with the FY2025 full-year figure at $468000.0, up 290.0% from the prior year.
- Asset Writedowns and Impairment fell to -$195000.0 in Q1 2026 per HROW's latest filing, from -$80000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $264000.0 in Q4 2023 and bottomed at -$195000.0 in Q1 2026.
- The 5-year median for Asset Writedowns and Impairment is $20000.0 (2023), against an average of $47411.8.
- Across the five-year window, Asset Writedowns and Impairment surged 4600.0% in 2022 and slumped 525.0% in 2024, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $45000.0 in 2022, then soared by 486.67% to $264000.0 in 2023, then tumbled by 46.97% to $140000.0 in 2024, then sank by 157.14% to -$80000.0 in 2025, then slumped by 143.75% to -$195000.0 in 2026.
- Per Business Quant, the three latest HROW Asset Writedowns and Impairment figures stand at -$195000.0 (Q1 2026), -$80000.0 (Q4 2025), and $208000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -195,000.00 |
| Mar 31, 2026 | -195,000.00 |
| Dec 31, 2025 | -80,000.00 |
| Dec 31, 2025 | -80,000.00 |
| Sep 30, 2025 | 208,000.00 |
| Sep 30, 2025 | 208,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 114,000.00 |
| Mar 31, 2025 | 114,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Dec 31, 2024 | 140,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | -85,000.00 |
| Mar 31, 2024 | -85,000.00 |
| Dec 31, 2023 | 264,000.00 |
| Dec 31, 2023 | 264,000.00 |